Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$909.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Shaun R. Bagai
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 17
- Beta
- 0.99
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 6.43
Financials
Revenue
$909.0K+2014.0%Net Income
$-2.91MEBITDA
$-2.91MFree Cash Flow
$-2.94MEPS (diluted)
$-0.06Shares Outstanding (diluted)
47.30M+303.2%Operating Expenses
$4.12MCash & Debt
$9.48MRevenue by Segment (annual)
$1.12MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.12M | $-11.17M | $-0.32 |
| 2024 | $43.0K | $-8.81M | $-0.37 |
| 2023 | $0.00 | $-10.23M | $-0.50 |
| 2022 | $0.00 | $-9.89M | $-0.54 |
| 2021 | $0.00 | $-6.32M | $-0.40 |
| 2020 | $0.00 | $-3.80M | $-0.25 |
| 2019 | $0.00 | $-3.84M | $-0.22 |
Valuation
RNXThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-80.43%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·5d ago·Negative
RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer Case Series Reports Tumor Treatment Response, Significant Tumor Marker Reduction, and Changes on Imaging After Treatment with TAMP in Patients with Unresectable LAPC Case Series Reports Tumor Treatment Response, Significant Tumor Marker Reduction, and Changes on Imaging After Treatment with TAMP in Patients with Unresectable LAPC
View source ↗ - Newsglobenewswire.com·42d ago·Negative
…ween Drug Metabolite Levels and Tumor Marker Reduction MOUNTAIN VIEW, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced the publication of pharmacokinetic and pharmacodynamic (PK/PD) data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial (NCT03257033) in the …
View source ↗ - Newsglobenewswire.com·46d ago·Neutral
…s Compliance with Nasdaq Minimum Bid Price Requirement MOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced that it has received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the minimum b…
View source ↗ - Newsglobenewswire.com·47d ago·Negative
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment As Commercial and Clinical Programs Advance, RenovoRx Continues to Strengthen its Global Intellectual Property Portfolio with 20 Issued or Allowed Patents and 13 Pending Patents to Support the Commercialization of RenovoCath As Commercial and Clinical Programs Advance, RenovoRx Continues to Strengthen its Global Intellect
View source ↗ - Newsmarketbeat.com·50d ago·Positive
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers RenovoRx NASDAQ: RNXT executives and physician speakers discussed the treatment landscape for locally advanced pancreatic cancer, the company's Trans-Arterial Micro-Perfusion, or TAMP, platform, and commercialization progress for its RenovoCath delivery device during a webinar hosted by JonesTrading.
View source ↗ - Newsmarketbeat.com·54d ago·Neutral
RenovoRx Q2 Earnings Call Highlights RenovoRx NASDAQ: RNXT reported record second-quarter revenue as it expanded its commercial cancer-center network and advanced its clinical program for locally advanced pancreatic cancer.
View source ↗ - Newszacks.com·54d ago·Neutral
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.08 per share a year ago.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.05 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.05 vs $-0.07beat
- Thu, May 14$-0.08 vs $-0.08beat
- Mon, Mar 30$-0.08 vs $-0.08beat
- Thu, Nov 13$-0.08 vs $-0.08beat
- Thu, Aug 14$-0.08 vs $-0.08beat
- Thu, May 15$-0.08 vs $-0.08beat
Estimates and results for RNXT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RNXT officers and directors.
- Bought
- $790k
- Sold
- —
42 trades
0 trades
- Voll Markbought
- Marton Laurencebought
- Marton Laurencebought
- Bagai Shaunbought
- Bagai Shaunbought
- Voll Markbought
- Voll Markbought
- Agah Ramtinbought
58 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RNXT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.